Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(17):1242-1243; doi:10.1093/jnci/dji297
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hayasaka, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hayasaka, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Randomized Trial of Aspirin, Vitamin E Raises Questions for Future Chemoprevention Studies

Elana Hayasaka

The first 10% of the full text of this article appears below.

Randomized trials of aspirin and vitamin E as potential agents for cancer prevention draw support from epidemiologic and observational evidence. They both have a plausible biological mechanism—as an antioxidant, it seems natural that vitamin E may have the ability to protect people from cancer, and the nonsteroidal anti-inflammatory drug (NSAID) aspirin has already proven its ability to protect against heart disease and strokes. Not to mention that they are both widely available and already taken by many people.

"The dream was, wouldn't it be wonderful if [aspirin] also reduced the risk of cancer at the same time?" said Julie Buring, Sc.D., of Harvard Medical School and Brigham and Women's Hospital in Boston.

This summer, Buring and colleagues published two papers in the Journal of the American Medical Association . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?